Tomohiro Torii

Dr. Tomohiro Torii

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
HHHamdan Hamdan
Hamdan Hamdan
BLBrian C. Lim
Brian C. Lim
TTTomohiro Torii
Tomohiro Torii
AJAbhijeet Joshi
Abhijeet Joshi
MKMatthias Konning
Matthias Konning
MRMatthew N. Rasband
Matthew N. Rasband
Axon initial segments (AISs) generate action potentials and regulate the polarized distribution of proteins, lipids, and organelles in neurons. While the mechanisms of AIS Na+ and K+ channel clustering are understood, the molecular mechanisms that stabilize the AIS and control neuronal polarity remain obscure. Here, we use proximity biotinylation and mass spectrometry to identify the AIS proteome. We target the biotin-ligase BirA* to the AIS by generating fusion proteins of BirA* with NF186, Ndel1, and Trim46; these chimeras map the molecular organization of AIS intracellular membrane, cytosolic, and microtubule compartments. Our experiments reveal a diverse set of biotinylated proteins not previously reported at the AIS. We show many are located at the AIS, interact with known AIS proteins, and their loss disrupts AIS structure and function. Our results provide conceptual insights and a resource for AIS molecular organization, the mechanisms of AIS stability, and polarized trafficking in neurons.

16 July 2014 in Pediatrics International
Verified
Journal Article
Open access
PDF file
TTTomohiro Torii
Tomohiro Torii
YMYuki Miyamoto
Yuki Miyamoto
JYJunji Yamauchi
Junji Yamauchi
ATAkito Tanoue
Akito Tanoue
Pelizaeus–Merzbacher disease (PMD) is a rare leukodystrophy that causes severe dysmyelination in the central nervous system in infancy and early childhood. Many previous studies showed that various proteolipid protein 1 (plp1) mutations, including duplications, point mutations, and deletions, lead to oligodendrocyte dysfunction in patients with PMD. PMD onset and clinical severity range widely, depending on the type of plp1 mutation. Patients with PMD exhibit a delayed mental and physical development phenotype, but specific pharmacological therapy and clinical treatment for PMD are not yet well established. This review describes PMD pathology and establishment of new clinical treatment for PMD. These findings support the development of a new therapy for PMD and these treatments may improve the quality of life in patients with PMD.

19 July 2010 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
PDF file
JYJunji Yamauchi
Junji Yamauchi
TTTomohiro Torii
Tomohiro Torii
SKShinji Kusakawa
Shinji Kusakawa
ASAtsushi Sanbe
Atsushi Sanbe
KNKazuaki Nakamura
Kazuaki Nakamura
ATAkito Tanoue
Akito Tanoue

5 March 2013 in Science Signaling
Verified
Journal Article
Closed access
PDF file
YMYuki Miyamoto
Yuki Miyamoto
TTTomohiro Torii
Tomohiro Torii
NYNatsuki Yamamori
Natsuki Yamamori
TOToru Ogata
Toru Ogata
ATAkito Tanoue
Akito Tanoue
JYJunji Yamauchi
Junji Yamauchi
During neuronal development, axons navigate long distances, eventually forming precise connections with such targets as peripheral tissues. Dock6 is a guanine nucleotide exchange factor (GEF) that activates the Rho family guanosine triphosphatases Rac1 and Cdc42 to regulate the actin cytoskeleton. We found that phosphorylation of Ser1194 in Dock6 inhibited its GEF activity and suppressed axonal growth of embryonic sensory neurons and axon regeneration of postnatal sensory neurons in vitro and in vivo. At early developmental stages, when axons are growing, the protein phosphatase PP2A interacted with and dephosphorylated Dock6, thereby increasing the activity of Dock6. At later developmental stages, the abundance of the kinase Akt increased, resulting in the binding of Akt to Dock6 and the phosphorylation of Dock6 at Ser1194. In dorsal root ganglion neurons from mice lacking Dock6, reintroduction of Dock6 with a nonphosphorylatable S1194A mutation rescued axon extension but not branch number, whereas reintroduction of Dock6 with a phosphomimetic S1194E mutation resulted in premature branching. Thus, the phosphorylation status of Dock6 at Ser1194 determines whether it promotes axon extension or branching in sensory neurons, revealing interplay between kinase and phosphatase action on a Rho-GEF during axon growth.

1 July 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
TTTomohiro Torii
Tomohiro Torii
YMYuki Miyamoto
Yuki Miyamoto
ASAtsushi Sanbe
Atsushi Sanbe
KNKohji Nishimura
Kohji Nishimura
JYJunji Yamauchi
Junji Yamauchi
ATAkito Tanoue
Akito Tanoue
The formation of primitive adipose tissue is the initial process in adipose tissue development followed by the migration of preadipocytes into adipocyte clusters. Comparatively little is known about the molecular mechanism controlling preadipocyte migration. Here, we show that cytohesin-2, the guanine-nucleotide exchange factor for the Arf family GTP-binding proteins, regulates migration of mouse preadipocyte 3T3-L1 cells through Arf6. SecinH3, a specific inhibitor of the cytohesin family, markedly inhibits migration of 3T3-L1 cells. 3T3-L1 cells express cytohesin-2 and cytohesin-3, and knockdown of cytohesin-2 with its small interfering RNA effectively decreases cell migration. Cytohesin-2 preferentially acts upstream of Arf6 in this signaling pathway. Furthermore, we find that the focal adhesion protein paxillin forms a complex with cytohesin-2. Paxillin colocalizes with cytohesin-2 at the leading edges of migrating cells. This interaction is mediated by the LIM2 domain of paxillin and the isolated polybasic region of cytohesin-2. Importantly, migration is inhibited by expression of the constructs containing these regions. These results suggest that cytohesin-2, through a previously unexplored complex formation with paxillin, regulates preadipocyte migration and that paxillin plays a previously unknown role as a scaffold protein of Arf guanine-nucleotide exchange factor.

15 December 2006 in Glycobiology
Verified
Journal Article
Open access
PDF file
AIAkihiro Ishii
Akihiro Ishii
TITakeshi Ikeda
Takeshi Ikeda
SHSeiji Hitoshi
Seiji Hitoshi
IFIchiro Fujimoto
Ichiro Fujimoto
TTTomohiro Torii
Tomohiro Torii
KIKazuhiro Ikenaka
Kazuhiro Ikenaka
Biosynthesis of N-glycans varies significantly among tissues and is strictly regulated spatially and temporally within the tissue. The strict molecular mechanisms that are responsible for control of N-glycan synthesis remain largely unknown. We developed complementary deoxyribonucleic acid (cDNA) macroarray system and analyzed gene expression levels of more than 140 glycosyltransferases and glycosidases in the cerebral cortex from developing and adult mice. We also analyzed the relative amounts of major N-glycans present in the cerebral cortex and examined how the synthesis of N-glycans might be regulated through the expression of these genes. We demonstrated that the content of N-linked oligosaccharides dramatically changed during the course of brain development. Some of these changes could not be explained by alterations in the expression of the corresponding genes. For example, the amount of core fucosylated sugar chains in the early embryonic brain and the expression level of fucosyltransferase VIII, the only gene known to be responsible for core fucosylation, did not change proportionately. This result suggests that post-transcriptional regulation of this gene plays an important role in regulating its enzymatic activity. On the other hand, the amount of β1,3-galactose residue-containing sugar chains increased postnatally following an increase in the level of β1,3-galactosyltransferase messenger ribonucleic acid (mRNA). Furthermore, the amount of sugar chains with an outer fucose residue, containing LewisX-BA-2, correlated well with the expression of fusocyltransferase IX mRNA. These findings add to our understanding of the molecular mechanisms responsible for the regulation of N-glycan biosynthesis in the cerebral cortex.